Literature DB >> 21264686

What, how, and when to offer nonresectional therapy for colorectal cancer liver metastases.

Cherif Boutros1, N Joseph Espat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21264686     DOI： 10.1007/s11605-011-1428-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN： 1091-255X            Impact factor:   3.452


× No keyword cloud information.
  8 in total

1.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.

Authors:  B Gray; G Van Hazel; M Hope; M Burton; P Moroz; J Anderson; V Gebski
Journal:  Ann Oncol       Date:  2001-12       Impact factor: 32.976

2.  A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.

Authors:  D C Hohn; R J Stagg; M A Friedman; J F Hannigan; A Rayner; R J Ignoffo; P Acord; B J Lewis
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

3.  Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.

Authors:  Guy Van Hazel; Anthony Blackwell; James Anderson; David Price; Paul Moroz; Geoff Bower; Giuseppe Cardaci; Bruce Gray
Journal:  J Surg Oncol       Date:  2004-11-01       Impact factor: 3.454

4.  Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases.

Authors:  Alice R Gillams; William R Lees
Journal:  J Vasc Interv Radiol       Date:  2008-03-17       Impact factor: 3.464

Review 5.  Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature.

Authors:  Sean Garrean; Justin Hering; Abdul Saied; W Scott Helton; N Joseph Espat
Journal:  Am J Surg       Date:  2008-04       Impact factor: 2.565

6.  Hepatic tumor ablation with clustered microwave antennae: the US Phase II trial.

Authors:  David A Iannitti; Robert C G Martin; Caroline J Simon; William W Hope; William L Newcomb; Kelly M McMasters; Damian Dupuy
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

8.  Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.

Authors:  Matthew Bower; Tiffany Metzger; Ken Robbins; Dana Tomalty; Vlatimil Válek; Jean Boudný; Tomas Andrasina; Cliff Tatum; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647
  8 in total
  4 in total

1.  SSAT/AHPBA Joint Symposium: Today's approaches to colorectal cancer (CRC) liver metastases.

Authors:  W Scott Helton
Journal:  J Gastrointest Surg       Date:  2011-02-01       Impact factor: 3.452

2.  Thermal tumor ablation therapy for colorectal cancer hepatic metastasis.

Authors:  Sanjay Munireddy; Steven Katz; P Somasundar; N Joseph Espat
Journal:  J Gastrointest Oncol       Date:  2012-03

3.  SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques.

Authors:  Olivier Riou; Carmen Llacer Moscardo; Pascal Fenoglietto; Emmanuel Deshayes; Raphaël Tetreau; Jessica Molinier; Alexis Lenglet; Eric Assenat; Marc Ychou; Boris Guiu; Norbert Aillères; Ludovic Bedos; David Azria
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-06

4.  Integrating respiratory-gated PET-based target volume delineation in liver SBRT planning, a pilot study.

Authors:  Olivier Riou; Benjamin Serrano; David Azria; Benoit Paulmier; Remy Villeneuve; Pascal Fenoglietto; Antonella Artenie; Cécile Ortholan; Marc Faraggi; Juliette Thariat
Journal:  Radiat Oncol       Date:  2014-06-02       Impact factor: 3.481
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.